Stem cell therapy represents a promising platform for clinical advancements in areas where current pharmacological and surgical treatment options are ineffective. In recent years cell therapies have evolved and matured, moving from academia to industry to market.
Scale up of a process is the natural path of the evolution of product development and maturation, and allows higher manufacturing capacity and yields to meet demands and to reduce of the cost of goods.
Standard methods for culturing stem cells use culture dishes, micro-carrier beads or other adherence surfaces, since the majority of stem cell types require attachment to a solid matrix and/or feeder cells support. These methods are highly labor-intensive, expensive and limited in the yields they can offer.
Accellta's suspension culture technologies enable mass production and differentiation of stem cells in bioreactors without adherence surfaces. The technologies have been extensively studied in pluripotent stem cells (PSCs), both embryonic (ESCs) and induced (iPSCs) from a variety of sources.
The technologies are estimated to reduce the cost of pluripotent stem cell mass manufacturing and differentiation by over a tenfold and to shorten the duration by more than a third.